Tegobuvir
- Generic Name
- Tegobuvir
- Drug Type
- Small Molecule
- Chemical Formula
- C25H14F7N5
- CAS Number
- 1000787-75-6
- Unique Ingredient Identifier
- 5NOK5X389M
- Background
Tegobuvir has been investigated for the treatment of Hepatitis C, Chronic.
GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: placebo to match tegobuvirDrug: placebo to match RBV
- First Posted Date
- 2011-09-16
- Last Posted Date
- 2013-12-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 170
- Registration Number
- NCT01435226
- Locations
- 🇺🇸
Advanced Clinical Research Institute, LLC, Anaheim, California, United States
🇺🇸Lightsource Medical, Los Angeles, California, United States
🇺🇸Medical Associates Research Group, Inc., San Diego, California, United States
GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection
- Conditions
- Chronic Genotype 1a or 1b HCV Infection
- Interventions
- Drug: GS-5885 tabletDrug: GS-9451 tabletDevice: placebo matching tegobuvir capsule
- First Posted Date
- 2011-09-15
- Last Posted Date
- 2013-12-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 163
- Registration Number
- NCT01434498
- Locations
- 🇺🇸
Kaiser Permanente Medical Center, Los Angeles, California, United States
🇺🇸Medical Associates Research Group, Inc., San Diego, California, United States
🇺🇸Kaiser Permanente, San Diego, California, United States
GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2011-05-13
- Last Posted Date
- 2013-12-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 141
- Registration Number
- NCT01353248
- Locations
- 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Digestive Health Specialists of the Southeast, Dothan, Alabama, United States
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: GS-9451 placeboBiological: Pegasys®
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 245
- Registration Number
- NCT01271790
- Locations
- 🇺🇸
Henry Ford Health System-Columbus center, Novi, Michigan, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Medical Associates Research Group, San Diego, California, United States
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
- Conditions
- Chronic Hepatitis C Infection
- Interventions
- Drug: GS-9190 placeboBiological: Pegasys®
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 324
- Registration Number
- NCT01225380
- Locations
- 🇺🇸
UT Southwestern Medical Center at Dallas, Dallas, Texas, United States
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
🇺🇸Medical Associates Research Group, San Diego, California, United States
Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection
- Conditions
- HCV Infection
- Interventions
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2012-05-31
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 46
- Registration Number
- NCT01072695
Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
- Conditions
- HCV Infection
- Interventions
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2013-11-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 252
- Registration Number
- NCT00743795
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.